Kim Papp’s Post

Clexio Biosciences is pleased to announce that we have reached 50% enrollment in our CLE-400 Phase 2 proof-of-concept study, in subjects suffering from chronic pruritus associated with Notalgia Paresthetica.   The study is a randomized, double-blind, vehicle-controlled multi-center study, enrolling in the US, assessing the efficacy and safety of our CLE-400 topical gel.   Notalgia Paresthetica is a type of sensory neuropathy associated with chronic itch in the upper back. Patients’ quality of life, sleep, and mood can be negatively impacted by this condition. To-date, there are no approved treatments for this condition.   CLE-400 is a topical formulation containing a potent α2-adrenergic agonist, a non-opioid and non-steroid. CLE-400 is an investigational drug and is currently not approved for commercial distribution. For more information on CLE-400: https://lnkd.in/dQ-GJkwE #clexio #clinicaltrials #notalgiaparesthetica #itch #dermatology #neuropathy

In recognition of #MelanomaAwarenessMonth, AMLo Biosciences are sharing (to US-only audience) a patient case study demonstrating the clinical utility of their #AMBLor technology that accurately stratifies early-stage, low-risk melanomas. https://lnkd.in/eehgYpVY AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers

Today is the first day of EADV in Amsterdam, and I am excited to share that Galderma will be presenting compelling new data from the ARCADIA and OLYMPIA clinical trial programs investigating nemolizumab in atopic dermatitis and prurigo nodularis. These data will be presented later today in three oral presentations. To learn more about the late breaking data from these pivotal trials, please read more here: https://lnkd.in/d8tE4JJ4 #ScienceBackedInnovation #AdvancingDermatology

The latest #psoriasis slide decks are now available on the #IMIDForum! Explore new insights and data to enhance your practice with the top research in #dermatology: [LINK] This month’s Literature Highlights are now available on the Immune-Mediated Inflammatory Disease Forum! November’s single slide summary includes a study by Huang, et al., where they aimed to identify predictors and construct a predictive model for time to relapse following withdrawal from biologics. Find out more about this publication, and more about #psoriasis on the IMID Forum today. 🔗https://ow.ly/z06850UhCMV

PEGASUS’ was a randomised double blind placebo controlled #trial of a Bruton Tyrosine Kinase Inhibitor (BTKI) in pemphigus. Rilzabrutinib is a reversible BTKI. In this global study, new onset and recalcitrant pemphigus vulgaris (PV-90%) and foliaceus (PF-10%) patients were treated with medium doses of prednisone (o.5 mg/kg/d) and randomised to rilza vs placebo. The primary outcome was the proportion of PV patients in Complete remission (no lesions- PDAI zero for at least 8 weeks) on minimal therapy at week 37. In this original protocol, p<0.05 but the trial was completed during the pandemic and FDA mandated excluding patients with remote visits and that minimal therapy be increased to 10mg/d pred; with these restrictions, p>0.05. Murrell et al https://lnkd.in/dNg8iNrU #derm #RCT #pemphigus #rilzabrutinib #clinicaltrial #phase3 #outcomes #PDAI #safety #international #dermatology #principiabio #sanofi #BTKI The PEGASUS study was conducted from January 8, 2019 through October 8, 2021, in 19 countries (Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Poland, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom, and United States).

I'm excited to share that our recent review article "Laser-mediated solutions: breaking barriers in transdermal drug delivery" has been published. Laser devices, as novel drug delivery systems, have been studied for their positive impact on drug absorption by creating microchannels through the epidermis, referred to as microthermal treatment zones (MTZs). By customizing laser parameters, CO2 and erbium-doped yttrium aluminum garnet (Er:YAG) lasers can be widely used in skin-related problems. In this article, we provide an overview of utilizing lasers as a drug delivery system for complications such as basal cell carcinoma, alopecia, and concerns related to laser use. I am appreciative of the assistance provided by Dr.Ashkan Barfar for valuable guidance, @Abolfazl Afaghmehr and @Niloofar Heydari for their efforts throughout the process, and Dr.Javad Shokri for steering this work as the corresponding author. Special thanks to the reviewers and editors of the AAPS PharmSciTech journal for shaping this article with their guidance. Link: https://rdcu.be/dLwKC #Laser, #transdermal, #novel, #dermatology, #derm, #drug_delivery, #drug_delivery_system, #laser_assisted_drug_delivery

Sharayu Kachare and I are excited to highlight our latest insights into the innovative advancements in psoriasis treatment!" Did you know that new treatments for psoriasis are changing the way we manage this challenging skin condition? Psoriasis affects millions of people worldwide, often leading to discomfort and a reduced quality of life. As a healthcare professional, staying updated on the latest treatment options is crucial to improving patient outcomes. In our latest clinical review, we explore the advancements in both topical and systemic treatments for psoriasis. From new topical formulations to cutting-edge biologics and JAK inhibitors, this article dives into the most recent innovations, their mechanisms, and their clinical benefits. #Psoriasis #Dermatology #Healthcare #ClinicalReview #InnovativeTreatments

Androgenetic alopecia, which affects both men and women, is hair loss influenced by genetic and hormonal factors. It can lead to a significant drop in body satisfaction and quality of life. At present, treatment options are limited, with treatments such as minoxidil and finasteride, which can slow hair loss, but do not necessarily restore original hair density.   Eurofins bioskin is present in AGA research, with proven expertise: ◾ +20 years' experience in AGA clinical trials ◾ 2000 patients treated, with men and women in our specialized clinical units ◾ Supervision by experienced dermatologists and physicians ◾ Mastery of validated TrichoLAB ® and Canfield systems, for precise analysis of hair growth ◾ Ability to manage complex studies on multiple forms of alopecia areata ◾ Exclusive database and rapid recruitment process for large volumes of patients   Learn more about our services ➡ https://lnkd.in/eK7JN9RE   #Eurofins #bioskin #Alopecia #ClinicalTrials #Innovation #Dermatology

#Psoriasis affects 125 million people worldwide. It’s more than a skin condition—it can impact every aspect of life, bringing both physical discomfort and emotional strain. 🤝 This #WorldPsoriasisDay, we’re stepping up to support those living with plaque psoriasis, which accounts for 80-90% of cases. 📍 At Scinai Immunotherapeutics Ltd., we are dedicated to transforming psoriasis care. Our drug development program focuses on a targeted therapy specifically for mild to moderate plaque psoriasis. Leveraging single-domain antibodies (sdAbs), including our anti-IL-17A/F sdAb, we are advancing a locally administered biologic that combines high potency and convenience with a safer profile than current treatments. 👉 Join us in raising awareness and supporting those affected by psoriasis. Together, we can make a difference for millions. 🌐 Visit Scinai.com to learn more #InnovativeResearch #Healthcare #Biotechnology #Dermatology #WorldPsoriasisDay24